Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: A secondary analysis of the GeparTrio trial data

Journal of Clinical Oncology

Volumn 28, Issue 1, 2010, Pages 83-91

  Dan Costa, Serban ^a   Loibl, Sibylle ^a   Kaufmann, Manfred ^a   Zahm, Dirk Michael ^a   Hilfrich, Jörn ^a   Huober, Jens ^a   Eidtmann, Holger ^a   Du Bois, Andreas ^a   Blohmer, Jens Uwe ^a   Ataseven, Beyhan ^a   Weiss, Erich ^a   Tesch, Hans ^a   Gerber, Bernd ^a   Baumann, Klaus H ^a   Thomssen, Christoph ^a   Breitbach, Georg Peter ^a   Ibishi, Shaip ^a   Jackisch, Christian ^a   Mehta, Keyur ^a   Von Minckwitz, Gunter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; NAVELBINE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER SIZE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG RESPONSE; FEMALE; HUMAN; INFLAMMATION; INFLAMMATORY BREAST CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; SECONDARY ANALYSIS; TREATMENT OUTCOME; ADJUVANT THERAPY; AGED; BREAST TUMOR; COMPARATIVE STUDY; CONTROLLED STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES;

EID: 73949155195     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.5101     Document Type: Article

References (25)

1. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 24:1940-1949, 2006
2. Chia S, Swain SM, Byrd DR, et al: Locally advanced and inflammatory breast cancer. J Clin Oncol 26:786-790, 2008
3. Cristofanilli M, Valero V, Buzdar AU, et al: Inflammatory breast cancer (IBC) and patterns of recurrence: Understanding the biology of a unique disease. Cancer 110:1436-1444, 2007
4. Beriwal S, Schwartz GF, Komarnicky L, et al: Breast-conserving therapy after neoadjuvant chemotherapy: Long-term results. Breast J 12:159-164, 2006
5. Clark J, Rosenman J, Cance W, et al: Extending the indications for breast-conserving treatment to patients with locally advanced breast cancer. Int J Radiat Oncol Biol Phys 42:345-350, 1998
6. Chen AM, Meric-Bernstam F, Hunt KK, et al: Breast conservation after neoadjuvant chemotherapy: The M. D. Anderson Cancer Center experience. J Clin Oncol 22:2303-2312, 2004
7. Brouwers B, Paridaens R, Lobelle JP, et al: Clinicopathological features of inflammatory versus noninflammatory locally advanced nonmetastatic breast cancer. Tumour Biol 29:211-216, 2008
8. Panades M, Olivotto IA, Speers CH, et al: Evolving treatment strategies for inflammatory breast cancer: A population-based survival analysis. J Clin Oncol 23:1941-1950, 2005
9. Valero VV, Buzdar AU, Hortobagyi GN: Locally advanced breast cancer. Oncologist 1:8-17, 1996
10. Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 20:3628-3636, 2002
11. von Minckwitz G, Kümmel S, Vogel P, et al: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: Phase III randomized GeparTrio trial. J Natl Cancer Inst 100:542-551, 2008
12. von Minckwitz G, Kümmel S, Vogel P, et al: Intensified neoadjuvant chemotherapy in early-responding breast cancer: Phase III randomized GeparTrio study. J Natl Cancer Inst 100:552-562, 2008
13. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21:843-850, 2003
14. Frasci G, D'Aiuto G, Comella P, et al: Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support versus triweekly epirubicin and paclitaxel in locally advanced breast cancer: Final analysis of a SICOG phase III study. Br J Cancer 95:1005-1012, 2006
15. Ellis GK, Barlow WE, Russell CA, et al: SWOG 0012, a randomized phase III comparison of standard doxorubicin and cyclophosphamide followed by weekly paclitaxel versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol 24:12s, 2006 (suppl; abstr LBA537)
16. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al: Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: The M. D. Anderson Cancer Center experience. Clin Breast Cancer 4:415-419, 2004
17. von Minckwitz G, Rezai M, Loibl S, et al: Trastuzumab improves pathologic complete response rate of neoadjuvant EC-docetaxel treatment in HER2 over-expressing breast cancer: Results of the phase III GeparQuattro study. 2008 Breast Cancer Symposium Proceedings 198, 2008 (abstr 226)
18. Kaufmann M, von Minckwitz G, Bear HD, et al: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: New perspectives 2006. Ann Oncol 18:1927-1934, 2007
19. Diagnosis and treatment of patients with primary and metastatic breast cancer: Complete guideline of the AGO Breast Commission 2009. http://www.ago-online.de/index.php?lang=de&site=mamma-guide- topical&topic=mamma-guide
20. Shen J, Valero V, Buchholz TA, et al: Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 11:854-860, 2004
21. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, et al: Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer 106:1000-1006, 2006
22. Gianni L, Semiglazov V, Manikhas GM, et al: Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumor and safety analysis. J Clin Oncol 25:10s, 2007 (suppl; abstr 532)
23. Johnston S, Trudeau M, Kaufman B, et al: Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26:1066-1072, 2008
24. Low JA, Yang SX, Chow CK, et al: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24:769-777, 2006
25. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998